Detail akcie Pulse Biosciences online

Business Summary: Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Pulse Biosciences Inc revenues decreased from $700K to $0K. Net loss decreased 28% to $42.2M. Revenues reflect Systems segment decrease from $560K to $0K, Cycle units segment decrease from $140K to $0K, North America segment decrease from $517K to $0K, Rest of World segment decrease from $183K to $0K. Lower net loss reflects Stock-based Compensation in decrease from $733K (expense) to $0K.